Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants

Ketamine, at sub-anesthetic doses, is reported to rapidly decrease depression symptoms in patients with treatment-resistant major depressive disorder (MDD). Many patients do not respond to currently available antidepressants, (for example, serotonin reuptake inhibitors), making ketamine and its enan...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotroff, D M, Corum, D G, Motsinger-Reif, A, Fiehn, O, Bottrel, N, Drevets, W C, Singh, J, Salvadore, G, Kaddurah-Daouk, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048196/
https://www.ncbi.nlm.nih.gov/pubmed/27648916
http://dx.doi.org/10.1038/tp.2016.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048196/
https://www.ncbi.nlm.nih.gov/pubmed/27648916
http://dx.doi.org/10.1038/tp.2016.145

Ejemplares similares